Bihua Chen's Net Worth

$1.18 Billion

Who is Bihua Chen?

Bihua Chen has an estimated net worth of $1.18 Billion. This is based on reported shares across multiple companies, which include Corbus Pharmaceuticals Holdings, Inc., MoonLake Immunotherapeutics, Turning Point Therapeutics, Inc., Vigil Neuroscience, Inc., Prometheus Biosciences, Inc., Ambrx Biopharma, Inc., Design Therapeutics, Inc., Kezar Life Sciences, Inc., Icosavax, Inc., Atea Pharmaceuticals, Inc., Kiniksa Pharmaceuticals, Ltd., Ventyx Biosciences, Inc., Axonics Modulation Technologies, Inc., Tyra Biosciences, Inc., Erasca, Inc., Monte Rosa Therapeutics, Inc., Verve Therapeutics, Inc., Aerovate Therapeutics, Inc., Avidity Biosciences, Inc., Apellis Pharmaceuticals, Inc., Immuneering Corp, Pyxis Oncology, Inc., Elevation Oncology, Inc., PROTEOSTASIS THERAPEUTICS, INC., BioAtla, Inc., Ambrx Biopharma Inc., Biomea Fusion, Inc., Rain Therapeutics Inc., Akouos, Inc., Cellectar Biosciences, Inc., Olema Pharmaceuticals, Inc., Clearside Biomedical, Inc., GreenLight Biosciences Holdings, PBC, CONSTELLATION PHARMACEUTICALS INC, and EyePoint Pharmaceuticals, Inc..

SEC CIK

Bihua Chen's CIK is 0001599214

Past Insider Trading and Trends

2023 was Bihua Chen's most active year for acquiring shares with 69 total transactions. Bihua Chen's most active month to acquire stocks was the month of May. 2021 was Bihua Chen's most active year for disposing of shares, totalling 16 transactions. Bihua Chen's most active month to dispose stocks was the month of October. 2023 saw Bihua Chen paying a total of $284,755,164.62 for 17,676,566 shares, this is the most they've acquired in one year. In 2021 Bihua Chen cashed out on 17,518,032 shares for a total of $3,753,000.00, their largest year based on trade value.